The Changing Landscape of HIV Prevention
What the Pharmacist Needs to Know about PrEP
Meeting Slides
Clinical Practice Guidelines
Guidance and resources during disruption of STD clinical services; update on STD treatment options.
Centers for Disease Control and Prevention; May 2020.
2018 quick reference guide: recommended laboratory HIV testing algorithm for serum or plasma specimens.
CDC Stacks. Centers for Disease Control and Prevention; last updated January 2018.
2015 sexually transmitted diseases treatment guidelines.
Centers for Disease Control and Prevention, 2015; last reviewed December 2019.
Updated guidelines for antiretroviral postexposure prophylaxis after sexual, injection drug use, or other nonoccupational exposure to HIV—United States, 2016.
CDC Stacks. Centers for Disease Control and Prevention; last updated May 2018. Accessed May 1, 2020.
HIV testing guidelines.
Centers for Disease Control and Prevention; 2020.
HIV testing in retail pharmacies (training for pharmacists and pharmacy staff).
Centers for Disease Control and Prevention; 2020.
Standards of Care for the Health of Transsexual, Transgender, and Gender Nonconforming People.
Coleman E, et al. 7th ed. East Dundee, Illinois: World Professional Association for Transgender Health; 2012.
Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society-USA Panel.
Saag MS, et al. JAMA. 2018;320(4):379-396.
ASHP [American Society of Health-System Pharmacists] guidelines on pharmacist involvement in HIV care.
Schafer JJ, et al. Am J Health Syst Pharm. 2016;73(7):468-494.
Guidelines for prevention and treatment of opportunistic infections in adults and adolescents with HIV.
US Department of Health and Human Services; revised May 2020.
Guidelines for the use of antiretroviral agents in adults and adolescents with HIV.
US Department of Health and Human Services; last updated December 2019.
Preexposure prophylaxis for the prevention of HIV infection in the United States—2017 update. A clinical practice guideline.
US Public Health Service. Centers for Disease Control and Prevention; 2018.
Professional Resources
American Academy of HIV Medicine; supporting the HIV care provider and the profession.
California Legislative Information. SB-159 HIV: preexposure and postexposure prophylaxis. October 2019.
Resources to support California’s Expanded Scope of Practice for Pharmacists.
California Department of Public Health (CDPH) Office of AIDS. PrEP Assistance Program resources.
Basic statistics.
Centers for Disease Control and Prevention; July 2020.
HIV in the United States by region.
Centers for Disease Control and Prevention; July 2020.
HIV and youth.
Centers for Disease Control and Prevention; May 2020.
Pre-exposure prophylaxis (PrEP).
Centers for Disease Control and Prevention; May 2020.
Taking a sexual history.
Centers for Disease Control and Prevention; April 2020.
Database of antiretroviral drug interactions.
HIV InSite. University of California, San Francisco; 2019.
PrEP to prevent HIV and promote sexual health.
New York State Department of Health AIDS Institute, Clinical Guidelines Program; February 2020.
Sexual History Taking Toolkit; July 2020.
TargetHIV.
Ending the HIV epidemic: Ready, Set, PrEP.
US Department of Health and Human Services.
Center of Excellence for Transgender Health.
Prevention Science, Department of Medicine; University of California, San Francisco; June 2020.
National Clinician Consultation Center.
University of California, San Francisco; 2020.
HIV drug interactions.
University of Liverpool (website); August 2020.
Patient Resources
HIV basics.
Centers for Disease Control and Prevention; June 2020.
HIV risk reduction tool. How can I prevent getting or transmitting HIV?
Centers for Disease Control and Prevention; June 2020.
Positively Aware.
Positively Aware, created by TPAN (Test Positive Aware Network), is a source of HIV-treatment news for consumers, as well as an educational tool for HIV caregivers. The site features PrEP resources, including videos for men who have sex with men and transgender people.
Prevention for women. Resources on HIV prevention for U.S. women.
HIVE online; 2019.
HIV resources.
National Institutes of Health.
UCSF transgender care.
University of California, San Francisco
Suggested Readings
Emtricitabine/tenofovir alafenamide; January 2020.
AIDS Info. US Department of Health and Human Services.
Emtricitabine/tenofovir disoproxil fumarate; July 2020.
AIDS Info. US Department of Health and Human Services.
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Baeten JM, et al. N Engl J Med. 2012;367(5):399-410.
Stigma, medical mistrust, and perceived racism may affect PrEP awareness and uptake in black compared to white gay and bisexual men in Jackson, Mississippi and Boston, Massachusetts.
Cahill S, et al. AIDS Care. 2017;29(11):1351-1358.
Assessing the efficacy and feasibility of a retail pharmacy-based HIV testing program.
Collins BC, et al. 24th Conference on Retroviruses and Opportunistic Infections (CROI) 2017; February 13-17, 2017; Seattle, WA. Abstract 962.
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Choopanya K, et al. Lancet. 2013;381(9883):2083-2090.
Being PrEPared – preexposure prophylaxis and HIV disparities.
Goldstein RH, et al. N Engl J Med. 2018;379(14):1293-1295.
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Grant RM, et al. N Engl J Med. 2010;363(27):2587-2599.
The phase 3 DISCOVER study: daily F/TAF or F/TDF for HIV preexposure prophylaxis.
Hare CB, et al. 26th CROI 2019; March 4-7, 2019; Seattle, WA. Abstract 104.
Lifetime risk of a diagnosis of HIV infection in the United States.
Hess KL, et al. Ann Epidemiol. 2017;27(4):238-243.
PrEParing to end the HIV epidemic—California's route as a road map for the United States.
Kazi DS, et al. N Engl J Med. 2019;381(26):2489-2491.
Community pharmacy delivered PrEP to STOP HIV transmission: an opportunity NOT to miss!
Lopez MI, et al. J Am Pharm Assoc (2003). 2020;60(4):e18-e24.
Why don't patients take their drugs? The role of communication, context and culture in patient adherence and the work of the pharmacist in HIV/AIDS.
Penn C, et al. Patient Educ Couns. 2011;83(3):310-318.
4 findings from a successful HIV PrEP program.
Ross M. Accessed July 30, 2020.
Phase 3 randomized, controlled DISCOVER study of daily F/TAF or F/TDF for HIV pre-exposure prophylaxis: week 96 results.
Ruane P, et al. 17th European AIDS Conference (EACS); November 6-9, 2019; Basel, Switzerland. Poster PE3/16.
Interdisciplinary care team with pharmacist in a community-based HIV clinic.
Samuel O, et al. J Natl Med Assoc. 2018;110(4):378-383.
Trends in the San Francisco human immunodeficiency virus epidemic in the "Getting to Zero" era.
Scheer S, et al. Clin Infect Dis. 2018;66(7):1027-1034.
How to incorporate HIV PrEP into your practice.
Stewart J, Stekler JD. J Fam Pract. 2019;68(5):254-261.
Implementation of a community pharmacy-based pre-exposure prophylaxis service: a novel model for pre-exposure prophylaxis care.
Tung EL, et al. Sex Health. 2018;15(6):556-561.
HIV testing in community pharmacies and retail clinics: a model to expand access to screening for HIV infection.
Weidle PJ, et al. J Am Pharm Assoc. 2014; 54(5):486-492.
Interactive PresentationAre you PrEP’d to Discuss Sexual Health & HIV Prevention?
This innovative live activity is designed for PCPs to practice their skills in sexual health discussions and HIV prevention via a simulated tele-visit with a standardized patient, trained to simulate the signs, symptoms, and behaviors of patients seen in daily practice. Earn 0.5 CME/CE credit. Click here for more information!
Preventing HIV Infection in the Pharmacy Setting
Information You Need to Keep Your Practice Up to Date
Relevant Resources
Overcoming Pain and Gastrointestinal Distress to Improve Patient Outcomes
Evidence-Based Strategies for Improved Patient Outcomes
Proactive Diagnosis and Targeted Management
Differential Diagnosis and Comprehensive Management Strategies
Optimizing Maintenance Therapy Across Healthcare Settings
Evolving Strategies for Diagnosis and Long-Term Management
Consensus and Controversies for Responsible Opioid Prescribing
Best Practices in Combination Therapy
Evolving Approaches to Insulin Based Therapy
Improving Outcomes for Patients with COPD
New Strategies for Insulin Replacement Therapy
Clinical Updates in LDL-C Management
Improving Comprehensive Patient Care
Identifying Patients and Tailoring Therapy
Collaborative Approaches to Guideline-Concordant Patient Care
New Strategies for Individualizing Long-term Care
A Focus on Patients With Opioid-Induced Constipation
Consensus and Controversies Across the Spectrum of Patient Presentations
Evolving Treatment Algorithms and Expert Perspectives on Biosimilars
Evolving Best Practices to Optimize Outcomes
The PCPs Role in Preventing HIV
The PCP’s Role in Timely Recognition and Referral
What Do You Know About PrEP?
Optimizing Use of Clinical Evidence & Pharmacoeconomic Models in Managed Care
What Do You Know About PrEP?
Got it? Treat it!
The Critical Role of the Community Pharmacist
Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships.
Volume 1: Rapid ART Initiation: A New Addition to the HIV-Care Tool Box
Differential Diagnosis, Multidisciplinary Management, and Patient Engagement
Key Issues Impacting OB/GYN Practice
Hot Topics in HBV, HCV, and NASH
Volume II: Expanding Evidence for the Role of Rapid ART Initiation in HIV Practice
Why It Matters in OB/GYN Practice Today
Improving Patient Outcomes Through Shared Clinical Decision Making
A Treater’s Guide to Optimizing Care in the Aging Patient with Comorbidities
How the Pharmacist Can Make a Difference
Mechanistic Insights and Evolving Treatment Options
HIV Can Be Prevented— Are You Doing Your Part?
Rapid Start ART — A New Model for HIV Care
Clinical Resource Center
Understanding the Growing Syndemic — Opioids, HCV, and HIV
A Case-Based Conversation on Managing Asthma and Chronic Rhinosinusitis With Nasal Polyposis
The Clinical and Utilization Benefits of Exacerbation Prevention
A PrEP Primer
A Foundation for Managed Care
Cardiovascular and Renal Outcomes With SGLT2 Inhibitors
Best Practices for Primary Care
New Paths to Chronic Pain Management
The PCP’s Role in HCV Elimination
The Rapid ART Standard of Care: From Evidence to Healthcare Equity
Unlocking Novel Paths to Patient Care
Maximizing Your Role to Impact Patient Outcomes
Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV
Benefits, Barriers, & Best Practices in an Advancing Field
Practical Solutions Across the Spectrum of Care
A PEP/PrEP Training Guide for Pharmacists
The Increasing Role of JAK Inhibitors
Preventing COPD Exacerbations to Improve Outcomes
A Critical Step Toward HCV Elimination
Considering the Patient, the Provider, and the Science
A Multidisciplinary Online Mini-Curriculum
A Whole Patient Case Series
Debates and Discussions about Monoclonal Antibody Therapies
An Update on Monoclonal Antibody Therapies
Establishing Clinical Readiness Through Mentored Learning
Interdisciplinary Strategies for Adult and Pediatric Patients
